HomeNewsBusinessStocksAjanta Pharma shares fall 1.3%, among top losers on Nifty Midcap 150 in early trade
Trending Topics

Ajanta Pharma shares fall 1.3%, among top losers on Nifty Midcap 150 in early trade

With the stock currently trading at Rs 2,580.00, Ajanta Pharma is facing selling pressure in today's session, joining other stocks in the Nifty Midcap 150 index that are experiencing declines.

September 08, 2025 / 09:47 IST
Story continues below Advertisement
Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer

Shares of Ajanta Pharma were trading down by 1.3% at Rs 2,580.00 in early trade on Monday, making it one of the top losers on the Nifty Midcap 150 index. Other stocks that saw losses include Sundaram Fin, New India Assur, Endurance Techn and Supreme Ind.

 

Financials (Consolidated)Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025
RevenueRs 1,144.92 CroreRs 1,186.64 CroreRs 1,146.13 CroreRs 1,170.41 CroreRs 1,302.65 Crore
Net ProfitRs 245.77 CroreRs 216.48 CroreRs 232.88 CroreRs 225.26 CroreRs 255.34 Crore
EPS19.5417.2718.6018.0020.44

 

Ajanta Pharma's revenue for the quarter ending June 2025 stood at Rs 1,302.65 Crore, compared to Rs 1,144.92 Crore in June 2024, marking an increase. The net profit for the same period was Rs 255.34 Crore, up from Rs 245.77 Crore in the corresponding quarter of the previous year. The EPS for June 2025 was Rs 20.44, compared to Rs 19.54 in June 2024.

Story continues below Advertisement

 

Financials (Consolidated)20212022202320242025
RevenueRs 2,889.69 CroreRs 3,340.99 CroreRs 3,742.64 CroreRs 4,208.71 CroreRs 4,648.10 Crore
Net ProfitRs 653.87 CroreRs 712.68 CroreRs 587.98 CroreRs 816.17 CroreRs 920.39 Crore
EPS75.0982.4545.8964.8273.56
BVPS344.52380.24268.14282.34302.38
ROE21.8221.8317.3522.8724.28
Debt to Equity0.000.000.000.000.00

 

Looking at the yearly data, Ajanta Pharma's revenue for the year ending March 2025 was Rs 4,648.10 Crore, up from Rs 4,208.71 Crore in March 2024. The net profit increased to Rs 920.39 Crore from Rs 816.17 Crore. The EPS stood at 73.56, compared to 64.82 in the previous year. The company’s debt-to-equity ratio remained at 0.00 for the year ending March 2025.